Search

Your search keyword '"Fabbrocini, G"' showing total 1,553 results
Start Over Author "Fabbrocini, G"
1,553 results on '"Fabbrocini, G"'

154. Creation of a severity index for hidradenitis suppurativa that includes a validated quality‐of‐life measure: the HIDRAscore

Author

Marzano, A.V., primary, Chiricozzi, A., additional, Giovanardi, G., additional, Argenziano, G., additional, Bettoli, V., additional, Bianchi, L., additional, Dapavo, P., additional, Dini, V., additional, Fabbrocini, G., additional, Micali, G., additional, Offidani, A.M., additional, Potenza, C., additional, Prignano, F., additional, Gualberti, G., additional, Saragaglia, V., additional, and Rongioletti, F., additional

Published
2020
Full Text
View/download PDF

158. Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*

Author

Marzano, A.V., primary, Genovese, G., additional, Casazza, G., additional, Moltrasio, C., additional, Dapavo, P., additional, Micali, G., additional, Sirna, R., additional, Gisondi, P., additional, Patrizi, A., additional, Dini, V., additional, Bianchini, D., additional, Bianchi, L., additional, Fania, L., additional, Prignano, F., additional, Offidani, A., additional, Atzori, L., additional, Bettoli, V., additional, Cannavò, S.P., additional, Venturini, M., additional, Bongiorno, M. R., additional, Costanzo, A., additional, Fabbrocini, G., additional, and Peris, K., additional

Published
2020
Full Text
View/download PDF

165. Chilblain-like lesions (COVID-19 toes) have the same impact on family members than psoriasis systemically treated: insights from a case-control study targeting the pediatric population.

Author

DAMIANI, G., FINELLI, R., KRIDIN, K., PACIFICO, A., BRAGAZZI, N. L., MALAGOLI, P., FABBROCINI, G., BONIFAZI, E., MAZZOTTA, F., LOVATI, C., SAVOIA, P., GIRONI, L. C., MORELLO, M., DAVIDSON, T., WATAD, A., GOKER, F., MORTELLARO, C., and DEL FABBRO, M.

Abstract

OBJECTIVE: COVID-19 toes represent the main dermatological COVID-19 cutaneous manifestation in pediatric patients. Its diagnosis exposes the whole family to social stigma and this aspect was not previously evaluated. PATIENTS AND METHODS: This was a multicenter, case-control, observational study that compared the family impact of COVID-19 toes vs. psoriasis (PsO). We enrolled 46 pediatric patients (23 with psoriasis and 23 with COVID-19 toes, age and gender matched) and their parents/caregivers that had to fill the Dermatitis Family Impact (DFI) questionnaire. RESULTS: DFI index did not differ significantly between both subgroups (p=0.48), and in psoriatic patients did not correlate with both Psoriasis Area Severity Index (PASI) (p=0.59) and itchVAS (p=0.16). CONCLUSIONS: COVID-19 toes, a transitory dermatosis, exerted a similar impact/perturbation on family dynamics than PsO, a well-known stigmatizing, chronic inflammatory dermatosis. [ABSTRACT FROM AUTHOR]

Published
2022

168. HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa

Author

Chiricozzi, Andrea, Bettoli, V., De Pita, O., Dini, V., Fabbrocini, G., Monfrecola, G., Musumeci, M. L., Parodi, A., Sampogna, F., Pennella, A., Buzzulini, F., Gualberti, G., di Luzio Paparatti, U., Atzori, L., Chiricozzi A. (ORCID:0000-0002-6739-0387), Chiricozzi, Andrea, Bettoli, V., De Pita, O., Dini, V., Fabbrocini, G., Monfrecola, G., Musumeci, M. L., Parodi, A., Sampogna, F., Pennella, A., Buzzulini, F., Gualberti, G., di Luzio Paparatti, U., Atzori, L., and Chiricozzi A. (ORCID:0000-0002-6739-0387)

Published
2019

169. Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients

Author

Fabbrocini, G., Marasca, C., Megna, M., Peris, Ketty, Amerio, P., Ardigo, M., Argenziano, G., Berti, Emanuele, Bettoli, V., Bianchi, L., Bongiorno, M. R., Cacciapuoti, S., Calzavara Pinton, P., Cannavo, S. P., Costanzo, Rosa Maria Alba, Cusano, F., Donini, M., Fierro, M. T., Lo Re, M., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Pigatto, P., Pimpinelli, N., Potenza, C., Romanelli, Margherita, Rongioletti, F., Stingeni, L., Peris K. (ORCID:0000-0002-5237-0463), Berti E., Costanzo A., Romanelli M., Fabbrocini, G., Marasca, C., Megna, M., Peris, Ketty, Amerio, P., Ardigo, M., Argenziano, G., Berti, Emanuele, Bettoli, V., Bianchi, L., Bongiorno, M. R., Cacciapuoti, S., Calzavara Pinton, P., Cannavo, S. P., Costanzo, Rosa Maria Alba, Cusano, F., Donini, M., Fierro, M. T., Lo Re, M., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Pigatto, P., Pimpinelli, N., Potenza, C., Romanelli, Margherita, Rongioletti, F., Stingeni, L., Peris K. (ORCID:0000-0002-5237-0463), Berti E., Costanzo A., and Romanelli M.

Abstract

Background: Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disease characterized by a significant impairment of patients’ quality of life (QoL). It has been recently found that clinical severity of HS does not correlate well with QoL. Therefore, it is important to enhance the evaluation of severity considering the disease burden on QoL. Recently, a new graphical tool able to better describe HS burden, the so-called HIDRAdisk, has been introduced. Objective: To investigate the utility of HIDRAdisk in clinical practice before and after treatment and to analyse whether specific factors such as age and gender may influence the outcomes in patients with moderate-to-severe HS. Methods: A single-centre retrospective study on 24 patients (13F/11M, mean age 38 ± 15 years) with moderate-to-severe HS was performed. Clinical data (disease severity and quality of life) were collected at baseline and after 12 weeks of adalimumab. Results: HIDRAdisk showed significantly better improvements in males (69.8 ± 6.2–49.6 ± 10.8) compared to females (80.7 ± 6.0–72.3 ± 6.7), P <0.001. A significant correlation was found in the total population between HS severity values measured through the modified Sartorius score (mSS) and QoL measured through HIDRAdisk. As regards the relationship between disease outcomes and age, a trend for better HIDRAdisk outcomes in younger patients (<40 years) compared to older ones was observed. Conclusions: HIDRAdisk appears as a complete and informative tool which can easily measure the global burden of HS, guiding treatment choice and evaluating its efficacy.

Published
2019

170. Italian guidelines in diagnosis and treatment of alopecia areata

Author

Rossi, A., Muscianese, M., Piraccini, B. M., Starace, M., Carlesimo, M., Mandel, V. D., Alessandrini, A., Calvieri, S., Caro, G., D'Arino, A., Federico, A., Magri, F., Pigliacelli, F., Amendolagine, G., Annunziata, M. C., Arisi, M. C., Astorino, S., Babino, G., Bardazzi, F., Barruscotti, S., Belloni Fortina, A., Borghi, A., Bruni, F., Caccavale, S., Calzavara-Pinton, P., Cameli, N., Cardone, M., Carugno, A., Coppola, R., Dattola, A., De Felici Del Giudice, M. B., Di Cesare, A., Dika, E., Dinunno, D., D'Ovidio, R., Fabbrocini, G., Feliciani, C., Fulgione, E., Galluzzo, M., Garcovich, S., Garelli, V., Guerriero, C., Hansel, K., La Placa, M., Lacarrubba, F., Lora, V., Marinello, E., Megna, M., Micali, G., Misciali, C., Monari, P., Monfrecola, G., Neri, I., Offidani, A., Orlando, G., Papini, M., Patrizi, A., Piaserico, S., Rivetti, N., Simonetti, O., Stan, T. R., Stingeni, L., Talamonti, M., Tassone, F., Villa, L., Vincenzi, C., Fortuna, M. C., Garcovich S. (ORCID:0000-0001-8967-6688), Guerriero C., Rossi, A., Muscianese, M., Piraccini, B. M., Starace, M., Carlesimo, M., Mandel, V. D., Alessandrini, A., Calvieri, S., Caro, G., D'Arino, A., Federico, A., Magri, F., Pigliacelli, F., Amendolagine, G., Annunziata, M. C., Arisi, M. C., Astorino, S., Babino, G., Bardazzi, F., Barruscotti, S., Belloni Fortina, A., Borghi, A., Bruni, F., Caccavale, S., Calzavara-Pinton, P., Cameli, N., Cardone, M., Carugno, A., Coppola, R., Dattola, A., De Felici Del Giudice, M. B., Di Cesare, A., Dika, E., Dinunno, D., D'Ovidio, R., Fabbrocini, G., Feliciani, C., Fulgione, E., Galluzzo, M., Garcovich, S., Garelli, V., Guerriero, C., Hansel, K., La Placa, M., Lacarrubba, F., Lora, V., Marinello, E., Megna, M., Micali, G., Misciali, C., Monari, P., Monfrecola, G., Neri, I., Offidani, A., Orlando, G., Papini, M., Patrizi, A., Piaserico, S., Rivetti, N., Simonetti, O., Stan, T. R., Stingeni, L., Talamonti, M., Tassone, F., Villa, L., Vincenzi, C., Fortuna, M. C., Garcovich S. (ORCID:0000-0001-8967-6688), and Guerriero C.

Abstract

Alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable and current available treatments have variable efficacy. Nowadays, there is relatively little evidence on treatment of AA from well-designed clinical trials. Moreover, none of the treatments or devices commonly used to treat AA are specifically approved by the Food and Drug Administration. The Italian Study Group for Cutaneous Annexial Disease of the Italian Society of dermatology proposes these Italian guidelines for diagnosis and treatment of Alopecia Areata deeming useful for the daily management of the disease. This article summarizes evidence-based treatment associated with expert-based recommendations.

Published
2019

171. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa

Author

Peris, Ketty, Lo Schiavo, A., Fabbrocini, G., Dini, Veronica, Patrizi, A., Fusano, M., Bianchi, L., Guanziroli, Eleonora, Guarneri, C., Parodi, A., Bertoldi, A., Musumeci, M. L., Offidani, A., Rongioletti, F., Pistone, G., Malara, G., Potenza, C., Casari, A., Franchi, C., Ardigo, M., Cusano, F., Stingeni, L., Amerio, P., Mancini, L. L., Prignano, F., Deboli, T., Gualberti, G., Saragaglia, V., Bettoli, V., Peris K. (ORCID:0000-0002-5237-0463), Dini V., Guanziroli E., Peris, Ketty, Lo Schiavo, A., Fabbrocini, G., Dini, Veronica, Patrizi, A., Fusano, M., Bianchi, L., Guanziroli, Eleonora, Guarneri, C., Parodi, A., Bertoldi, A., Musumeci, M. L., Offidani, A., Rongioletti, F., Pistone, G., Malara, G., Potenza, C., Casari, A., Franchi, C., Ardigo, M., Cusano, F., Stingeni, L., Amerio, P., Mancini, L. L., Prignano, F., Deboli, T., Gualberti, G., Saragaglia, V., Bettoli, V., Peris K. (ORCID:0000-0002-5237-0463), Dini V., and Guanziroli E.

Abstract

Background: Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disease characterized by painful inflamed nodules, recurrent abscesses and fistulas located in apocrine gland–bearing body sites. The negative impact of HS on patient's quality of life (QoL) has been reported to be greater than other dermatologic conditions as psoriasis and atopic eczema, and its improvement is an important goal in disease management. Nowadays, there are no specific validated QoL instruments available for HS and generic dermatologic questionnaires are used. Objective: The objective of this study was to demonstrate the validity, reliability and responsiveness of HIDRAdisk, a new innovative tool designed for rapid assessment of HS burden and, at the same time, an intuitive graphic visualization of the measurement outcome. Methods: A multicentre, longitudinal, observational study was conducted to validate the HIDRAdisk compared with other validated questionnaires [Skindex-16, Dermatology Life Quality Index (DLQI), Work Productivity and Activity Impairment–General Health (WPAI:GH)] and to evaluate its correlation with disease severity in Italian patients with any degree of HS severity, as measured by Hurley stage and HS Physician Global Assessment (HS-PGA). Results: A total of 140 patients (59% women; mean age 34.9 ± 11.0 years) were enrolled in 27 dermatologic centres. HIDRAdisk showed a strong correlation with Skindex-16 and DLQI, and a good one with WPAI:GH (correlation coefficient: 0.7568, 0.6651 and 0.5947, respectively) and a statistically significant correlation with both Hurley stage and HS-PGA. Very good internal consistency (Cronbach coefficient >0.80; intraclass correlation coefficient >0.6), with correlation between the 10 items, good test–retest reliability (Spearman correlation coefficient, 0.8331; P < 0.0001) and responsiveness to changes were demonstrated. Conclusion: Our study shows that HIDRAdisk, a short and innovativ

Published
2019

172. Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light

Author

Ribero, S., Dapavo, P., Casalegno, C., Alaibac, M., Argenziano, G., Arpaia, N. G., Bagnoni, G., Berti, Emanuele, Bianchi, L., Bianchini, D., Calzavara Pinton, P., Cannavo, S. P., Congedo, Maria Teresa, Corrao, S., Costanzo, Rosa Maria Alba, Cusano, F., Dattola, S., Dattoli, S., Deledda, S., Donini, M., Fabbrocini, G., Teresa Fierro, M., Foti, C., Galluccio, A. G., Gatti, A., Rene Girardelli, C., Girolomoni, G., Lemme, G., Malagoli, P., Malara, G., Mercuri, S. R., Micali, G., Montesu, M. A., Offidani, A., Papini, M., Parodi, A., Patrizi, A., Pellacani, G., Peris, Ketty, Piccirillo, A., Pigatto, P., Pimpinelli, N., Potenza, C., Provenzano, Katia Elisabetta, Romanelli, Margherita, Rongioletti, F., Savoia, P., Simonacci, Matteo, Sirna, R., Stinco, G., Valenti, Gianfranco, Zalaudek, Iris, Berti E., Congedo M., Costanzo A., Peris K. (ORCID:0000-0002-5237-0463), Provenzano E., Romanelli M., Simonacci M., Valenti G., Zalaudek I., Ribero, S., Dapavo, P., Casalegno, C., Alaibac, M., Argenziano, G., Arpaia, N. G., Bagnoni, G., Berti, Emanuele, Bianchi, L., Bianchini, D., Calzavara Pinton, P., Cannavo, S. P., Congedo, Maria Teresa, Corrao, S., Costanzo, Rosa Maria Alba, Cusano, F., Dattola, S., Dattoli, S., Deledda, S., Donini, M., Fabbrocini, G., Teresa Fierro, M., Foti, C., Galluccio, A. G., Gatti, A., Rene Girardelli, C., Girolomoni, G., Lemme, G., Malagoli, P., Malara, G., Mercuri, S. R., Micali, G., Montesu, M. A., Offidani, A., Papini, M., Parodi, A., Patrizi, A., Pellacani, G., Peris, Ketty, Piccirillo, A., Pigatto, P., Pimpinelli, N., Potenza, C., Provenzano, Katia Elisabetta, Romanelli, Margherita, Rongioletti, F., Savoia, P., Simonacci, Matteo, Sirna, R., Stinco, G., Valenti, Gianfranco, Zalaudek, Iris, Berti E., Congedo M., Costanzo A., Peris K. (ORCID:0000-0002-5237-0463), Provenzano E., Romanelli M., Simonacci M., Valenti G., and Zalaudek I.

Abstract

Background: Hidradenitis suppurativa is an inflammatory skin disease that presents a recurrence of painful and suppurating lesions in the apocrine gland-bearing regions, with a strong impact on the patients’ life quality. Despite its peculiar presentation, early forms are often underestimated by patients and this would inevitably result in late diagnosis and delayed therapy. Objectives: Improved communication around the disease could facilitate self-diagnosis and a quicker response from healthcare practitioners, especially in this moment when we dispose of effective treatment against this disease. Methods: A HS awareness campaign was conducted for 2 years with the help of a media agency and a patients’ association. Results: Results confirm that a better communication has a strong impact on the disease awareness. Conclusions: This paper demonstrates that the more this disease awareness is carried on, the more quick, effective and efficient the patient's management could be.

Published
2019

179. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa

Author

Peris, K., primary, Lo Schiavo, A., additional, Fabbrocini, G., additional, Dini, V., additional, Patrizi, A., additional, Fusano, M., additional, Bianchi, L., additional, Guanziroli, E., additional, Guarneri, C., additional, Parodi, A., additional, Bertoldi, A., additional, Musumeci, M.L., additional, Offidani, A., additional, Rongioletti, F., additional, Pistone, G., additional, Malara, G., additional, Potenza, C., additional, Casari, A., additional, Franchi, C., additional, Ardigò, M., additional, Cusano, F., additional, Stingeni, L., additional, Amerio, P., additional, Mancini, L.L., additional, Prignano, F., additional, Deboli, T., additional, Gualberti, G., additional, Saragaglia, V., additional, and Bettoli, V., additional

Published
2019
Full Text
View/download PDF

182. Sex‐related differences of clinical features in hidradenitis suppurativa: analysis of an Italian‐based cohort

Author

Bianchi, L., primary, Caposiena Caro, R. D., additional, Ganzetti, G., additional, Molinelli, E., additional, Dini, V., additional, Oranges, T., additional, Romanelli, M., additional, Fabbrocini, G., additional, Monfrecola, G., additional, Napolitano, M., additional, Egan, C. G., additional, Musumeci, M. L., additional, Lacarrubba, F., additional, Micali, G., additional, Passoni, E., additional, Calzavara‐Pinton, P. G., additional, Venturini, M., additional, Zanca, A., additional, and Offidani, A. M., additional

Published
2018
Full Text
View/download PDF

185. BRIT‐1 expression and its relationship with PARP‐1 and CAF‐1/p60 in cutaneous melanoma.

Author

Russo, D., Travaglino, A., Varricchio, S., Merolla, F., Ilardi, G., Raffone, A., Scalvenzi, M., Costa, C., Fabbrocini, G., Staibano, S., and Mascolo, M.

Subjects
POLY(ADP-ribose) polymerase, POLY ADP ribose, MELANOMA
Abstract

Immunohistochemistry was performed with anti-BRIT-1 (mouse polyclonal antibody, diluted 1: 300 overnight at 4°C, Abcam), anti-PARP-1 and anti-CAF-1/p60 following the previously described methods.2,3 The expression of BRIT-1 was subdivided into "normal" (nuclear) vs "abnormal" (cytoplasmic or negative); nuclear expression of PARP-1 and CAF-1/p60 in >50% of CM cells was labelled as "overexpression". Consistently, most CM metastases (6/8, 75%) showed PARP-1 and CAF-1/p60 overexpression. Defect of BRCA1 C terminus-repeat inhibitor of human telomerase expression-1 (BRIT-1), a protein involved in DNA repair, appears to promote growth and aggressiveness of several human cancers.1 Mutations in the nuclear localization signals within the BRIT-1-encoding gene have been described, which may lead to an aberrant cytoplasmic localization of the protein.1 However, BRIT-1 has not yet been studied in cutaneous melanoma (CM). [Extracted from the article]

Published
2021
Full Text
View/download PDF

188. Reply to 'New‐onset cutaneous lichen planus triggered by COVID‐19 vaccination' by Merhy et al.

Author

Camela, E., Guerrasio, G., Patruno, C., Scalvenzi, M., Di Caprio, N., Fabbrocini, G., and Napolitano, M.

Subjects
COVID-19 vaccines, LICHEN planus, HEPATITIS B vaccines, INFLUENZA, ORAL lichen planus
Abstract

Reply to 'New-onset cutaneous lichen planus triggered by COVID-19 vaccination' by Merhy et al References 1 Merhy R, Sarkis AS, Kaikati J, El Khoury L, Ghosn S, Stephan F. New-onset cutaneous lichen planus triggered by COVID-19 vaccination. Lichenoid drug reaction following influenza vaccination in an HIV-positive patient: a case report and literature review. [Extracted from the article]

Published
2022
Full Text
View/download PDF

190. Comorbidities in pediatric alopecia areata.

Author

Conic, R.Z., Tamashunas, N.L., Damiani, G., Fabbrocini, G., Cantelli, M., and Bergfeld, W.F.

Subjects
ALOPECIA areata, CHILD patients, VITILIGO, DERMATOLOGISTS, VITAMIN D deficiency, MEDICAL care costs, MEDICAL records
Abstract

Background: Comorbidities are associated with higher health care costs, complex management, and poorer health outcomes. Identification and treatment of comorbid conditions in paediatric alopecia areata (AA) patients could provide an opportunity to improve health outcomes. Objectives: To determine the prevalence of comorbidities among paediatric patients with AA using a large de‐identified aggregated patient database. Methods: This is a cross‐sectional study using aggregated health record data through April 1, 2019. Patients ≤18 years of age, with alopecia areata (n = 3510) and without alopecia areata (n = 8 310 710) were identified. The primary outcome was the prevalence of comorbidities among AA patients. Results: Of the 8 314 220 paediatric patients, 3510 (1570 males and 1940 females) had a diagnosis of alopecia areata. The most common comorbidities included atopic dermatitis (17.4% vs. 2.2% controls, OR 9.2, 95% CI 8.55–10.18, P < 0.001), anaemia (7.7% vs. 2.4% controls, OR 3.4, 95% CI 3.06–3.92, P < 0.001), obesity (5.7% vs. 1.1% controls, OR 5.6, 95% CI 4.76–6.34, P < 0.001), vitamin D deficiency (5.1% vs. 0.4% controls, OR 14.7, 95% CI 13.5–18.1, P < 0.001), hypothyroidism (2.6% vs. 0.2% controls, OR 12, 95% CI 10.73–15.9, P < 0.001), vitiligo (1.4% vs. 0.04% controls, OR 32.2, 95% CI 24.01–42.1, P < 0.001), psoriasis (1.4% vs. 0.07% controls, OR 20.6, 95% CI 15.55–27.2, P < 0.001), hyperlipidemia (1.4% vs. 0.2% controls, OR 5.9, 95% CI 4.4–7.7, P < 0.001), and depression (2.6% vs. 0.6% controls, OR 4.8, 95% CI 5.09–9.45, P < 0.001). Conclusions: Findings from this study suggest that children with AA are more likely to have certain autoimmune and metabolic disorders than the general paediatric population. Paediatric AA patients display a severe burden of autoimmune and metabolic diseases, thus in daily practice, dermatologists might consider multidisciplinary management in these patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

191. Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic.

Author

Hansel, K., Patruno, C., Antonelli, E., Dal Bello, G., Napolitano, M., Fabbrocini, G., Grieco, T., Pellacani, G., Fargnoli, M. C., Esposito, M., Piras, V., Zucca, M., Girolomoni, G., and Stingeni, L.

Subjects
ATOPIC dermatitis, DUPILUMAB, COVID-19 pandemic, TEENAGERS
Abstract

Real-life data concerning dupilumab effectiveness and safety in adolescents (aged >= 12 to <18 years) with moderate to severe atopic dermatitis (AD) are rarely reported.1 In two adolescence studies, the phase III randomized, placebo-controlled, clinical trial (LIBERTY AD ADOL)2 and the phase IIa and subsequent phase III open-label extension (LIBERTY AD PED-OLE)3 dupilumab produced significant improvement in signs and symptoms at Week 16, with a good safety profile. The issue of dupilumab therapy was under debate during COVID-19 pandemic first wave.4 In the Italian experience on 1576 patients under dupilumab treatment, 15 patients contracted SARS-CoV-2 infection with a good clinical outcome, confirming that dupilumab should be continued during the COVID-19 pandemic.5 Nevertheless, systematic studies are needed to evaluate the effect of dupilumab in patients with SARS-CoV-2 infection. Two of our patients (22.2%) achieved completely clear skin, compared with none of patients included in the previous trials.2,3 Additionally, we observed a greater improvement in patients with low BMI and high EASI at baseline. [Extracted from the article]

Published
2022
Full Text
View/download PDF

192. Reply to "Psoriasis exacerbation after COVID‐19 vaccination: report of 14 cases from a single centre" by Sotiriou E et al.

Author

Megna, M., Potestio, L., Gallo, L., Caiazzo, G., Ruggiero, A., and Fabbrocini, G.

Subjects
COVID-19 vaccines, MEDICAL personnel, DISEASE exacerbation, PSORIASIS, SYNOVITIS, COVID-19, PSORIATIC arthritis
Abstract

However, our experience showed that psoriasis exacerbation after COVID-19 vaccination may also develop in patients undergoing biologic treatment, even if the risk is reduced and limited. The patients in this manuscript have given written informed consent to publication of their case details. Hence, patients undergoing topical treatment for psoriasis have a higher risk of psoriatic flares compared with patients treated with systemic drugs. [Extracted from the article]

Published
2022
Full Text
View/download PDF

196. Comparison of clinical and ultrasound scores in patients with hidradenitis suppurativa: results from an Italian ultrasound working group

Author

Napolitano, M., primary, Calzavara-Pinton, P.G., additional, Zanca, A., additional, Bianchi, L., additional, Caposiena Caro, R.D., additional, Offidani, A.M., additional, Ganzetti, G., additional, Molinelli, E., additional, Dini, V., additional, Oranges, T., additional, Romanelli, M., additional, Egan, C.G., additional, Fabbrocini, G., additional, Monfrecola, G., additional, Lacarrubba, F., additional, Musumeci, M.L., additional, Passoni, E., additional, Venturini, M., additional, and Micali, G., additional

Published
2018
Full Text
View/download PDF

198. HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa

Author

Chiricozzi, A., primary, Bettoli, V., additional, De Pità, O., additional, Dini, V., additional, Fabbrocini, G., additional, Monfrecola, G., additional, Musumeci, M.L., additional, Parodi, A., additional, Sampogna, F., additional, Pennella, A., additional, Buzzulini, F., additional, Gualberti, G., additional, di Luzio Paparatti, U., additional, and Atzori, L., additional

Published
2018
Full Text
View/download PDF

200. Molecular basis of pharmacological therapy in Cushing’s disease

Author

Ferone, Diego, Pivonello, Claudia, Vitale, Giovanni, Zatelli, Maria Chiara, Colao, Annamaria, Pivonello, Rosario, Albiger, ABC Group: N., Ambrogio, A., Arnaldi, G., Arvat, E., Baldelli, R., Berardelli, R., Boscaro, M., Cannavo', Salvatore, Cavagnini, F., Corsello, S. M., Cozzolino, A., De Bartolomeis, A., De Leo, M., Di Minno, G., Di Somma, C., Esposito, K., Fabbrocini, G., Foresta, C., Galderisi, M., Giordano, C., Giugliano, D., Giustina, A., Grimaldi, F., Isidori, A. M., Jannini, E., F. Lombardo, L. Manetti, Mannelli, M., Mantero, F., Marone, G., Mazziotti, G., Moretti, S., Nazzari, E., Paragliola, R. M., Pasquali, R., Pecorelli, S., Pecori Giraldi, F., Reimondo, G., Scaroni, C., Scillitani, A., Simeoli, C., Stigliano, A., Toscano, V., Trementino, L., Ferone, D, Pivonello, Claudia, Vitale, G, Zatelli, Mc, Colao, Annamaria, and Pivonello, Rosario

Subjects
business.industry, Endocrinology, Diabetes and Metabolism, Humans, Hypothalamus, Pituitary ACTH Hypersecretion, Pituitary Gland, Receptors, Glucocorticoid, Disease, Cushing's disease, medicine.disease, Bioinformatics, Clinical trial, Endocrinology, Pituitary adenoma, Diabetes mellitus, Immunology, medicine, Endocrine system, business, Receptor, Glucocorticoid, medicine.drug
Abstract

Cushing's disease (CD) is a severe endocrine condition caused by an adrenocorticotropin (ACTH)-pro- ducing pituitary adenoma that chronically stimulates adrenocortical cortisol production and with potentially serious complications if not or inadequately treated. Active CD may produce a fourfold increase in mortality and is associated with significant morbidities. Moreover, excess mortality risk may persist even after CD treatment. Although predictors of risk in treated CD are not fully understood, the importance of early recognition and ade- quate treatment is well established. Surgery with resection of a pituitary adenoma is still the first line therapy, being successful in about 60-70 % of patients; however, recur- rence within 2-4 years may often occur. When surgery fails, medical treatment can reduce cortisol production and ameliorate clinical manifestations while more definitive therapy becomes effective. Compounds that target hypo- thalamic-pituitary axis, glucocorticoid synthesis or adre- nocortical function are currently used to control the deleterious effects of chronic glucocorticoid excess. In this review we describe and analyze the molecular basis of the drugs targeting the disease at central level, suppressing ACTH secretion, as well as at peripheral level, acting as adrenal inhibitors, or glucocorticoid receptor antagonists. Understanding of the underlying molecular mechanisms in CD and of glucocorticoid biology should promote the development of new targeted and more successful therapies in the future. Indeed, most of the drugs discussed have been tested in limited clinical trials, but there is potential ther- apeutic benefit in compounds with better specificity for the class of receptors expressed by ACTH-secreting tumors. However, long-term follow-up with management of per- sistent comorbidities is needed even after successful treatment of CD.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results